Pharmaceutical company Journey Medical Corp. (DERM) announced Friday that the Company has submitted a New Drug Application or NDA, to the U.S. Food and Drug Administration or FDA, seeking approval for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults.